SYDNEY, Australia and
VILLEPINTE, France, March 24, 2014 /PRNewswire/ --
Sirtex Medical Limited (ASX: SRX) and Guerbet S.A. (GBT.PA) are
pleased to announce today that the two companies are entering into
a collaboration to advance research in primary and secondary
metastatic liver cancer. The objective of the collaboration is to
evaluate the unmet clinical need in patients with hepatocellular
carcinoma, metastatic colorectal cancer, neuroendocrine tumors, and
a range of other secondary liver cancers*.
Sirtex's Chief Medical Officer, David
Cade said that "Interventional Oncology is one of the
fastest growing and most exciting areas of innovation in cancer
care, giving patients with few or no treatment choices, an extended
lease on life while helping maintain their quality of life."
"We are looking forward to open new horizons in Interventional
Oncology and we are determined to explore a symbiotic clinical
research partnership as we relentlessly pursue our goal to help
patients with unresectable hepatic tumors" said Guerbet's US
General Manager, Massimo
Carrara.
Guerbet and Sirtex share a common vision to advance
interventional oncology by developing new approaches in patient
care and treatment algorithms that may revolutionize liver cancer
therapy in the future.
*The scope of collaboration and development activities between
Sirtex and Guerbet is currently being finalized, with additional
announcements expected to be made in 2014.
About Sirtex
Sirtex is a global life-sciences company that develops and
delivers effective oncology treatments using novel small particle
technology. Current research involving radio-protector technologies
and novel small particle technology are two areas of focus amongst
an expanding portfolio of products designed to offer cancer
patients treatment options in the management of their disease.
Sirtex devotes significant resources to the future growth of the
company with approximately 23% of $100
million in sales for 2013 invested in research and
development and clinical studies. Sirtex (SRX) is listed on the
Australian Stock Exchange. For additional information about Sirtex,
please go to http://www.sirtex.com.
About Guerbet
A pioneer in the field of contrast agents with more than 80
years of experience, Guerbet is the only pharmaceutical group fully
dedicated to medical imaging worldwide. As such it has a complete
offering of contrast products for X-ray and MRI and for
Interventional Radiology, along with a range of injectors and
related medical equipment to provide improved diagnosis and
treatment of patients. To promote the discovery of new products and
assure future growth, Guerbet devotes significant resources to
research and development every year (approximately 10% of sales).
Guerbet (GBT) is listed on the NYSE Euronext Paris (Eurolist
Segment B - Mid Caps) and had sales of €390 million in 2013 with a
total workforce of 1,485 employees. For additional information
about Guerbet please go to http://www.guerbet.com.
This press release may contain forward-looking statements
based on current assumptions and forecasts made by Sirtex and
Guerbet management. Various known and unknown risks, uncertainties
and other factors could lead to material differences between the
actual future results, financial situation, development or
performances of the company and the estimates given here. These
factors include those discussed in Sirtex and Guerbet's public
reports which are available on the Sirtex and Guerbet websites
at http://www.sirtex.com and http://www.guerbet.com.
The companies assume no liability whatsoever to update these
forward-looking-statements or to conform them to future events or
developments.
SOURCE Sirtex Medical Limited and Guerbet S.A.